Taysha director awarded RSUs and stock options

Taysha Gene Therapies director Phillip B. Donenberg reported equity compensation grants.

Rhea-AI Filing Summary

Taysha Gene Therapies director Phillip B. Donenberg reported equity compensation grants. He received 21,335 shares of Common Stock as a restricted stock unit award at no purchase price. These RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, if he continues serving as a director.

He was also granted a stock option covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these grants, he directly holds 241,289 shares of Common Stock.

Insider Trade Summary

Grant/Award: 64,006 shares

Grant/Award 2 txns

Insider Donenberg Phillip B.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	42,671	$0.00	$0.00
Grant/Award	Common Stock	21,335	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 42,671 contracts (Direct); Common Stock — 241,289 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
2. F2. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Key Figures

RSU award: 21,335 shares RSU vesting date: June 1, 2027 Stock options granted: 42,671 options +3 more

6 metrics

RSU award 21,335 shares Restricted stock units granted to director

RSU vesting date June 1, 2027 Or earlier at next annual stockholders meeting

Stock options granted 42,671 options Stock Option (right to buy) granted to director

Option exercise price $5.97 per share Exercise price of stock option grant

Option expiration June 1, 2036 Expiration date of stock option grant

Shares held after grants 241,289 shares Total Common Stock directly owned after transactions

Key Terms

restricted stock unit ("RSU"), Stock Option (right to buy), annual stockholders meeting

3 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award."

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of $5.9700."

annual stockholders meeting financial

"vest on the earlier of June 1, 2027 or the next annual stockholders meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Taysha Gene Therapies (TSHA) director Phillip Donenberg report in this Form 4?

Phillip B. Donenberg reported receiving equity compensation, including a restricted stock unit award and a new stock option grant. These awards increase his direct stake and potential future ownership in Taysha Gene Therapies, Inc.

How many RSUs did Phillip Donenberg receive from Taysha Gene Therapies (TSHA)?

He received 21,335 shares of Common Stock in the form of a restricted stock unit award. These RSUs vest based on continued service as a director and convert into shares when vesting conditions are met.

When do Phillip Donenberg’s Taysha Gene Therapies (TSHA) RSUs vest?

The RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting. Vesting is contingent on his continued service as a director through the applicable vesting date.

What are the key terms of Phillip Donenberg’s new Taysha (TSHA) stock option grant?

He received a stock option covering 42,671 shares of Common Stock at a $5.97 exercise price. The option expires on June 1, 2036 and can be exercised for shares if standard option conditions are satisfied.

How many Taysha Gene Therapies (TSHA) shares does Phillip Donenberg hold after these grants?

After the reported transactions, he directly holds 241,289 shares of Common Stock. This figure reflects his ownership position following the RSU and stock option awards disclosed in the Form 4.

Are Phillip Donenberg’s Taysha (TSHA) equity grants open-market purchases or compensation?

The transactions are compensation-related grants, not open-market trades. The Form 4 codes describe them as awards of restricted stock units and stock options provided in his capacity as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donenberg Phillip B.

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, SUITE 1430

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		21,335(1)	A	$0	241,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.97	06/01/2026		A		42,671		(2)	06/01/2036	Common Stock	42,671	$0	42,671	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

2. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

	/s/ Kamran Alam, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)